BRIEF published on 11/26/2025 at 00:51, 3 months 21 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 3 months 21 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 3 months 22 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 3 months 22 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 7 months 1 day ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
PRESS RELEASE published on 08/15/2025 at 13:27, 7 months 1 day ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 7 months 9 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 7 months 9 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 8 months 22 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 8 months 22 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
Published on 03/17/2026 at 08:20, 2 hours 43 minutes ago Nano One Advances Candiac LFP Production Capacity Expansion Project, Detailed Engineering & Equipment Procurement
Published on 03/17/2026 at 08:05, 2 hours 58 minutes ago BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
Published on 03/17/2026 at 08:01, 3 hours 2 minutes ago Star Copper Reports First Phase 2 Drill Results Extending Mineralization to West, North and South
Published on 03/16/2026 at 22:30, 12 hours 33 minutes ago Core Silver Intersects High-Grade Copper-Molybdenum Veins up to 7.31% Cu & 1.01% Mo Confirming Large Porphyry System at Laverdiere
Published on 03/17/2026 at 10:30, 33 minutes ago Bybit EU Cooperates with PayPal to Simplify Crypto Funding
Published on 03/17/2026 at 10:04, 59 minutes ago Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million
Published on 03/17/2026 at 10:02, 1 hour 1 minute ago ETH Learning Factory Zug: A new center for learning, research and practice at Tech Cluster Zug
Published on 03/17/2026 at 10:00, 1 hour 3 minutes ago Original-Research: SMARTBROKER HOLDING AG (von GBC AG): BUY
Published on 03/17/2026 at 10:00, 1 hour 3 minutes ago Swiss Re announces USD 2 billion longevity reinsurance transaction
Published on 03/17/2026 at 07:00, 4 hours 3 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 17 hours 3 minutes ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 17 hours 5 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 17 hours 7 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
